Phase III study of gefitinib (G) versus gefitinib+carboplatin+pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)

M. Seike, A. Inoue, S. Sugawara, S. Morita, Y. Hosomi, S. Ikeda, K. Watanabe, K. Takahashi, Y. Fujita, T. Harada, K. Minato, K. Takamura, K. Kobayashi, T. Nukiwa

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)viii496
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Publication statusPublished - 2018 Oct 1

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this